Recro Pharma Inc (REPH) Major Shareholder Sells $115,120.32 in Stock

Recro Pharma Inc (NASDAQ:REPH) major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $8.88, for a total value of $115,120.32. Following the transaction, the insider now directly owns 734,269 shares in the company, valued at $6,520,308.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Scp Vitalife Partners (Israel) also recently made the following trade(s):

  • On Friday, December 28th, Scp Vitalife Partners (Israel) sold 1,980 shares of Recro Pharma stock. The stock was sold at an average price of $9.44, for a total value of $18,691.20.

Recro Pharma Inc (REPH) traded up $0.02 during mid-day trading on Thursday, reaching $8.78. The company’s stock had a trading volume of 139,400 shares, compared to its average volume of 209,567. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50. Recro Pharma Inc has a 52 week low of $5.81 and a 52 week high of $10.59. The stock has a market cap of $167.91, a P/E ratio of -4.08 and a beta of -0.50.

Hedge funds have recently bought and sold shares of the business. JT Stratford LLC purchased a new stake in Recro Pharma during the 2nd quarter worth approximately $704,000. Goldman Sachs Group Inc. increased its holdings in Recro Pharma by 373.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 60,276 shares of the specialty pharmaceutical company’s stock worth $424,000 after purchasing an additional 47,557 shares during the last quarter. Vanguard Group Inc. increased its holdings in Recro Pharma by 14.2% during the 2nd quarter. Vanguard Group Inc. now owns 640,208 shares of the specialty pharmaceutical company’s stock worth $4,501,000 after purchasing an additional 79,520 shares during the last quarter. Northern Trust Corp increased its holdings in Recro Pharma by 428.5% during the 2nd quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock worth $1,254,000 after purchasing an additional 144,676 shares during the last quarter. Finally, Essex Investment Management Co. LLC increased its holdings in Recro Pharma by 40.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 93,199 shares of the specialty pharmaceutical company’s stock worth $837,000 after purchasing an additional 26,785 shares during the last quarter. Institutional investors own 61.55% of the company’s stock.

Several research firms recently commented on REPH. Zacks Investment Research raised Recro Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Piper Jaffray Companies reissued a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a research report on Friday, October 27th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $11.65.

COPYRIGHT VIOLATION WARNING: This article was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2018/01/04/recro-pharma-inc-reph-major-shareholder-sells-115120-32-in-stock.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply